肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
10期
664-666
,共3页
胃肿瘤%治疗%复胃汤%模型,动物
胃腫瘤%治療%複胃湯%模型,動物
위종류%치료%복위탕%모형,동물
Stomach neoplasms%therapy%Fuwei decoction%Models,animal
目的 探讨中药复胃汤预防和治疗胃癌前病变的机制和效果.方法 对140只胃癌前病变模型大鼠进行中药(复胃汤)和西药(维酶素)预防和治疗给药,观察胃黏膜病理改变和Caspase-3的变化.结果 中药及西药预防组不典型增生发生率分别为50.0％(6/12)、42.86％(6/14),明显低于造模组的90.0％(9/10)(H=16.40,H=16.86,均P＜0.05).中药及西药治疗组不典型增生发生率为42.9％(6/14)和41.7 ％(5/12),明显低于造模空白组的90.9 ％(10/11)(H=12.39,H=12.18,均P＜ 0.05),且多为轻、中度不典型增生[45.45％(6/11)、36.36％(4/11)].造模组Caspase-3表达明显低于正常对照组(q=3.05,P＜ 0.01),中药及西药预防组Caspase-3表达均增加,均明显高于造模组和正常对照组(q=5.45、q=7.54、q=8.51、q=10.60,均P＜ 0.01).中药及西药治疗组Caspase-3表达亦明显高于造模空白组和正常组,差异均有统计学意义(q=15.66、q=18.53、q=15.66、q=18.53,均P＜ 0.01).结论 复胃汤通过促进Caspase-3的表达,抑制了胃黏膜上皮细胞不典型增生,达到对胃癌前病变的防治作用.
目的 探討中藥複胃湯預防和治療胃癌前病變的機製和效果.方法 對140隻胃癌前病變模型大鼠進行中藥(複胃湯)和西藥(維酶素)預防和治療給藥,觀察胃黏膜病理改變和Caspase-3的變化.結果 中藥及西藥預防組不典型增生髮生率分彆為50.0％(6/12)、42.86％(6/14),明顯低于造模組的90.0％(9/10)(H=16.40,H=16.86,均P＜0.05).中藥及西藥治療組不典型增生髮生率為42.9％(6/14)和41.7 ％(5/12),明顯低于造模空白組的90.9 ％(10/11)(H=12.39,H=12.18,均P＜ 0.05),且多為輕、中度不典型增生[45.45％(6/11)、36.36％(4/11)].造模組Caspase-3錶達明顯低于正常對照組(q=3.05,P＜ 0.01),中藥及西藥預防組Caspase-3錶達均增加,均明顯高于造模組和正常對照組(q=5.45、q=7.54、q=8.51、q=10.60,均P＜ 0.01).中藥及西藥治療組Caspase-3錶達亦明顯高于造模空白組和正常組,差異均有統計學意義(q=15.66、q=18.53、q=15.66、q=18.53,均P＜ 0.01).結論 複胃湯通過促進Caspase-3的錶達,抑製瞭胃黏膜上皮細胞不典型增生,達到對胃癌前病變的防治作用.
목적 탐토중약복위탕예방화치료위암전병변적궤제화효과.방법 대140지위암전병변모형대서진행중약(복위탕)화서약(유매소)예방화치료급약,관찰위점막병리개변화Caspase-3적변화.결과 중약급서약예방조불전형증생발생솔분별위50.0％(6/12)、42.86％(6/14),명현저우조모조적90.0％(9/10)(H=16.40,H=16.86,균P＜0.05).중약급서약치료조불전형증생발생솔위42.9％(6/14)화41.7 ％(5/12),명현저우조모공백조적90.9 ％(10/11)(H=12.39,H=12.18,균P＜ 0.05),차다위경、중도불전형증생[45.45％(6/11)、36.36％(4/11)].조모조Caspase-3표체명현저우정상대조조(q=3.05,P＜ 0.01),중약급서약예방조Caspase-3표체균증가,균명현고우조모조화정상대조조(q=5.45、q=7.54、q=8.51、q=10.60,균P＜ 0.01).중약급서약치료조Caspase-3표체역명현고우조모공백조화정상조,차이균유통계학의의(q=15.66、q=18.53、q=15.66、q=18.53,균P＜ 0.01).결론 복위탕통과촉진Caspase-3적표체,억제료위점막상피세포불전형증생,체도대위암전병변적방치작용.
Objective To investigate the treatment of Fuwei decoction for the prevention of gastric precancerous lesions and to elucidate the possible mechanism and medical effect underlying the activity.Methods A total of 140 rats with gastric precancerous lesions were utilized through traditional Chinese medicine (CM) and Western medicine prevention and treatment,in order to observe the various clinical changes of gastric mucosal pathology and Caspase-3.Results The results showed that the incidence of atypical hyperplasia treated by TCM group was 50.0％ (6/12) and that by western medicine prevention group was 42.86％ (6/14),which was significantly lower than gastric mucosal rebuilding group [90.0％ (9/10)](H =16.40,H =16.86,p＜0.05).Compared with gastric mucosal rebuilding gap group 90.9 ％(10/11)(H =12.39,H =12.18,P ＜0.05),the incidence of atypical hyperplasia (A&H) underlying TCM group and western medicine prevention group were 42.9％(6/14)and 41.7％ (5/12),respectively,which much of them was further confirmed as mild and moderate A&H [45.45％ (6/11),36.36 ％(4/11)].Furthermore,also it was found that all the groups,turn out to express with obvious rate discrepancy underlying Caspase-3 as:(1) the rate of gastric mucosal rebuilding group was lower than regular comparison group (q =3.05,P ＜0.01); (2) the rate of TCM group & western medicine prevention group is much higher than gastric mucosal rebuilding group & regular comparison group (q =5.45,q =7.54,q =8.51,q =10.60,P ＜0.01); (3) the rate of TCM group & western medicine treatment group is also rather higher than gastric mucosal rebuilding gap group & regular comparison group (q =15.66,q =18.53,q =15.66,q =18.53,P ＜0.01).Conclusion The findings of the current study illustrate that the Fuwei decoction has a protective & preventive effect on gastric precancerous.which is against the atypical hyperplasia on gastric epithelial cells underlying Caspase-3.
